Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention

Colorectal Disease

Volumn 10, Issue 3, 2008, Pages 244-248

  Koss, Konrad ^a   Maxton, D ^b   Jankowski, J A Z ^c,d  

^a MACCLESFIELD DISTRICT GENERAL HOSPITAL   (United Kingdom)

^b ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Colorectal cancer; Faecal; M2 PK; Polyps; Pyruvate kinase; Screening

Indexed keywords

DIMER; MONOCLONAL ANTIBODY; PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COLON POLYP; COLORECTAL CANCER; COLORECTAL SURGERY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HUMAN; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLECTOMY; COLONIC POLYPS; COLORECTAL NEOPLASMS; FECES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; OCCULT BLOOD; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; PYRUVATE KINASE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 39649109698     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2007.01334.x     Document Type: Article

References (30)

1. Warburg O. (1930) Ueber den stoffwechsel der Tumouren. Constable, London.
2. Racker E. Warburg effect revisited. Science 1981; 213: 1313.
3. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-9.
4. Stubbs M, Bashford CL, Griffiths JR. Understanding the tumour metabolic phenotype in the genomic era. Curr Mol Med 2003; 3: 49-59.
5. 2 homeostasis. Curr Opin Genet Dev 1998; 8: 588-94.
6. Mazurek S, Zwerschke W, Jansen-Durr P et al. Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem J 2001; 356: 247-56.
7. Mazurek S, Zwerschke W, Jansen-Durr P, Eigenbrodt E. Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7. Oncogene 2001; 20: 6891-8.
8. Mazurek S, Grimm H, Oehmke M et al. Tumour M2-PK and glutaminolytic enzymes in the metabolic shift of tumour cells. Anticancer Res 2000; 20: 5151-4.
9. Birkenkamp-Demtroder K, Christensen LL, Harder OS et al. Gene expression in colorectal cancer. Cancer Res 2002; 62: 4352-63.
10. Board M, Humm S, Newsholme EA. Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. Biochem J 1990; 265: 503-9.
11. Mazurek S, Eigenbrodt E. The tumour metabolome. Anticancer Res 2003; 23: 1149-54.
12. Eigenbrodt E, Mazurek S, Friis R. (1998) Double role of pyruvate kinase type M2 in the regulation of phosphometabolite pools. In: Cell Growth and Oncogenesis (eds Bannasch P, Kanduc D, Papa S, Tager JM), pp. 15-30. Birkhäuser Verlag, Basel.
13. Koss K, Harrison RF, Gregory J et al. The metabolic marker tumour pyruvate kinase type M2 (Tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus. J Clin Pathol 2004; 57: 1156-9.
14. Schulze G. The tumour marker tumour M2-PK: An application in the diagnosis of gastrointestinal cancer. Anticancer Res 2000; 20: 4961-4.
15. Hardt PD, Toepler M, Ngoumou B et al. Measurement of fecal pyruvate kinase type M2 (Tumour M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003; 23: 851-3.
16. Ventrucci M, Cipolla A, Racchini C et al. Tumour M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 2004; 49: 1149-55.
17. Hardt PD, Mazurek S, Toepler M et al. Fecal tumour M2 pyruvate kinase: A new, sensitive screening tool for colorectal cancer. Br J Cancer 2004; 91: 980-4.
18. Vogel T, Driemel C, Hauser A et al. Comparison of different stool tests for the detection of cancer of the colon. Dtsch Med Wochenschr 2005; 130: 872-7.
19. Kanaoka S, Yoshida K, Miura N et al. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in faeces for colorectal cancer screening. Gastroenterology 2004; 127: 422-7.
20. Davidson LA, Jiang YH, Lupton JR et al. Noninvasive detection of putative biomarkers for colon cancer using fecal messenger RNA. Cancer Epidemiol Biomarkers Prev 1995; 4: 643-7.
21. Instruction manual; ScheBo. (2005) Tumour M2-PK Stool Test. ScheBo Biotech AG, Giessen, Germany.
22. Schneider J, Schulze G. Comparison of tumour M2-pyruvate kinase (Tumour M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res 2003; 23: 5089-93.
23. Hardt PD, Ngoumou BK, Rupp J et al. Tumour M2-pyruvate kinase: A promising tumour marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 2000; 20: 4965-8.
24. Mandel JS, Bond JH, Church JR et al. Reducing mortality for colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1365-71.
25. Hardcastle JD, Chamberlain JO, Robinson MHE et al. Randomised controlled trial of fecal occult blood screening for colorectal cancer. Lancet 1996; 348:1472-7.
26. Kronborg O, Fenger C, Olsen J et al. Randomised study of screening for colorectal cancer with fecal occult blood test. Lancet 1996; 348: 1467-71.
27. Steele RJ, Gnauck R, Hrcka R et al. Methods and economic considerations: Group 1 Report. ESGE/UEGF Colorectal Cancer-Public Awareness Campaign. Endoscopy 2004; 36: 349-53.
28. Lieberman DA, Harford WV, Ahnen DJ et al. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345: 555-60.
29. Lijmer JG, Mol BW, Heisterkamp S et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999; 282: 1061-6.
30. Jankowski JA, Hawk ET. A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 101-11.